Journal of Modern Oncology最新文献

{"title":"Solitary metastasis of colorectal cancer in the left adrenal gland 4 years after surgery on the primary tumor. Case report","authors":"M. Budurova, V.S. Trifanov, V.V. Kopylov, Olga S. Kuznetsova, M. Chernichenko, S. I. Poluektov","doi":"10.26442/18151434.2023.3.202355","DOIUrl":"https://doi.org/10.26442/18151434.2023.3.202355","url":null,"abstract":"Colorectal cancer (CRC) is one of the most common oncological diseases. On average, in 20–25% of cases after radical surgical treatment of CRC, the progression of the disease in the form of metachronous metastases in the liver and lungs, as the most common localization of CRC metastases, is noted in patients. With the advent of new drug treatment strategies for CRC, there is an increase in overall survival, as a result of which CRC metastases in the adrenal glands have become more common than previously thought, and the number of published reports of cases of CRC metastasis in the adrenal glands has increased. In this article, we report a rare clinical observation of metachronous solitary metastasis of CRC to the left adrenal gland 4 years after radical surgical treatment of the primary tumor: the patient underwent radical left-sided adrenalectomy. The period of observation of the patient without signs of progression and relapse of the disease is 6 months (at the time of publication).","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":"10 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138585027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world experience with trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and HER2-positive gastric cancer: A retrospective study","authors":"Vladimir I. Evdokimov, Anatoly A. Bloshchinenko, Alexander E. Abolmasov, Alexey A. Vilensky, Michail S. Laskov","doi":"10.26442/18151434.2023.3.202457","DOIUrl":"https://doi.org/10.26442/18151434.2023.3.202457","url":null,"abstract":"Aim. To evaluate the effectiveness of trastuzumab deruxtecan in real-world practice in the Russian Federation. \u0000Materials and methods. We performed a retrospective analysis of clinical case series related to the use of trastuzumab deruxtecan (N=15) in the setting of a single clinical center, University Headache Clinic (Dr. Laskov's Clinic), as part of the program for the import of an unapproved drug as a life-saving measure. The overall survival, progression-free survival, and objective response rate were assessed, and individual real-world cases of drug efficacy were presented. \u0000Results. Objective response rates are comparable to those shown in large randomized trials. The median follow-up was 67 days; the 6-month overall survival was 70.1% (95% confidence interval [CI] 49.4–99.6%), and the 6-month progression-free survival was 52.1% (95% CI 29.9–90.6%). There were no significant complications associated with therapy; in particular, no events of interstitial lung disease were reported. \u0000Discussion. The real-world efficacy of trastuzumab deruxtecan was comparable to that in randomized clinical trials. However, at the level of individual clinical cases, slightly lower efficacy was noted in initially frailer patients (ECOG score 3). Also, it should be noted that the study included patients who had the opportunity to purchase an expensive drug and, therefore, had a social status different from the general population, which could affect the results of this study. \u0000Conclusion. The use of trastuzumab deruxtecan in real-world settings has demonstrated high efficacy and a good safety profile.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":"4 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138585136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Memorial lecture to the 100th anniversary of the birth of Professor Yu.I. Lorie","authors":"Elena A. Demina, I. Poddubnaya","doi":"10.26442/18151434.2023.3.202409","DOIUrl":"https://doi.org/10.26442/18151434.2023.3.202409","url":null,"abstract":"In 2022, the 100th anniversary of the birth of Professor Yu.I. Lorie was celebrated. Yuri Ivanovich Lorie is a talented Russian internal medicine specialist and hematologist, a wonderful teacher, and a person of great personal charm. Yu.I. Lorie is the founder of a new direction of hematology in Russia – oncohematology – and the establisher of a school based on deep knowledge and understanding of the oncological principles of hematological malignancies. Yuri Ivanovich Lorie lived a short (only 54 years) but bright life, utterly devoted to Russian medicine. He left a great legacy – a modern, rapidly developing direction in Russian medicine and a school of students who successfully continued the work he started. Looking back at the scientific and practical activities of Yu.I. Lorie and those emotional scientific debates that his colleagues and students remember, it becomes clear how many modern trends in the understanding of oncogenesis, diagnosis and treatment of hematological malignancies this legendary scientist established.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":"4 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138584695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What is the accuracy of different combinations of ultrasound imaging and blood tests to diagnose ovarian cancer in women before and after the menopause?","authors":"","doi":"10.26442/18151434.2023.3.202451","DOIUrl":"https://doi.org/10.26442/18151434.2023.3.202451","url":null,"abstract":"This publication is the Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review: Davenport C, Rai N, Sharma P, Deeks JJ, Berhane S, Mallett S, Saha P, Champaneria R, Bayliss SE, Snell KIE, Sundar S. Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women. Cochrane Database of Systematic Reviews 2022, Issue 7. Art. No.: CD011964. DOI: 10.1002/14651858.CD011964.pub2. Accessed 12 October 2023.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138584736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International experience by using of the SJMB protocols in treatment of children with medulloblastoma in the age group over 3 years (literature review)","authors":"A. S. Levashov, S. Zagidullina, T. T. Valiev, A. Stroganova, Dmitry A. Khochenkov, V. Grigorenko, E. V. Mikhaylova, Elizaveta V. Tyurina, M. Ryzhova, Serhii Horielyshev, Shavkat U. Kadyrov, V. Polyakov","doi":"10.26442/18151434.2023.3.202437","DOIUrl":"https://doi.org/10.26442/18151434.2023.3.202437","url":null,"abstract":"During the last 30 years, unique international experience has been accumulated in the treatment of children with medulloblastoma, especially in the age group over 3 years. Evolutionary representations about one of the most well – known international protocols – SJMB (in versions since 1996 – SJMB96, since 2003 – SJMB03, since 2012 – SJMB12) are shown in this article. Innovative criteria for stratifying patients into risk groups were established according to clinical, therapeutic, morphological and molecular-biological prognostic factors. Despite the accumulated experience, it is necessary to continue studying the relationship between age groups and the molecular biology of tumor cells for the purpose of subsequent optimization of the treatment program.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138584986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular genetic markers of ovarian cancer tumor cells and their microenvironment, study methods, and clinical value: A review","authors":"M. A. Kalfa, I. Golovkin, Artem E. Lazarev, Lena P. Golubinskaya, O. Y. Gritskevich, E. Zyablitskaya","doi":"10.26442/18151434.2023.3.202422","DOIUrl":"https://doi.org/10.26442/18151434.2023.3.202422","url":null,"abstract":"Ovarian cancer (OC) is a common malignancy of the female reproductive system. In most patients, OC is diagnosed in the later stages, leading to an abysmal prognosis. The standard treatment for OC is surgery and chemotherapy; however, relapse often occurs after treatment, especially in patients with advanced disease. New therapeutic options based on advances in tumor genetics and molecular biology are needed to improve treatment outcomes. Manipulations with genes and the proteins they express, affecting oncogenesis and treatment resistance, seem promising, and proteins and gene fragments identified using molecular methods become valuable markers in the supportive pharmacodiagnosis and tailoring of complex therapy. This article describes the research achievements in genetic markers in OC.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":"2 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138584747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An interdisciplinary approach to the management of oncohematological patients with immunodeficiency: clinical cases. A review","authors":"L. Babicheva, A. V. Luntsov, G. Khusainova, I. Poddubnaya","doi":"10.26442/18151434.2023.3.202446","DOIUrl":"https://doi.org/10.26442/18151434.2023.3.202446","url":null,"abstract":"Immunodeficiency occurs when one or more immune system components do not function properly, resulting in the body's inability to resist mostly infectious agents. Most cases of immunodeficiency in adults are acquired (secondary), but congenital immunodeficiencies are not uncommon. Primary immunodeficiencies are a heterogeneous group of innate immune errors that result in various clinical and laboratory manifestations. In contrast, secondary immunodeficiencies involve an acquired decrease in immune cell count and/or impairment of their function, commonly associated with an antibody level decrease. Secondary immunodeficiency in patients with B-cell hematological malignancies is a common condition attributed to both hematological malignancy and secondary antitumor therapy-related causes. Paradoxically, immunodeficiency, initially attributed to secondary causes, may be due to a previously undiagnosed primary immunodeficiency. Early diagnosis of immunodeficiency and optimization of management strategies with a multidisciplinary approach are critical to providing the most effective specific treatments and reducing the incidence of infection-related complications and mortality. The article addresses clinical practice, recommendations, and problems of immunodeficiency diagnosis and the effectiveness of immunoglobulin replacement therapy illustrated by clinical cases.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":"9 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138585110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The frequency of regimens associated with high risk of febrile neutropenia and the incidence of dose-limiting neutropenia among patients receiving cytotoxic therapy for malignancies: the FLAME study results","authors":"Anton V. Snegovoy, Inessa B. Kononenko, Irina V. Sorokina, A. Berezina, Oxana N. Prosianikova","doi":"10.26442/18151434.2023.3.202452","DOIUrl":"https://doi.org/10.26442/18151434.2023.3.202452","url":null,"abstract":"Aim. To assess the proportion and profile of patients at high risk of febrile neutropenia (FN) receiving cytotoxic chemotherapy (CT), as well as the incidence of FN and dose-limiting neutropenia after one cycle of CT. \u0000Materials and methods. The paper presents the results of the FLAME study, the first Russian observational study in patients with solid tumors who received only cytotoxic CT or a combination with targeted, immuno-oncological drugs. By random sampling, the study retrospectively included 500 patients with a median age of 59 years (18–83 years) from 25 medical institutions in the Russian Federation. \u0000Results. CT regimens with a high (20%) risk of FN were received by 25.2% (126/500) of patients; 53% (265/500) of patients had intermediate risk, and half of them (132/265 [49.8%]) had at least one additional risk FN factor following international NCCN guidelines. Thus, a high risk of FN, according to the therapy and the assessment of individual prognostic adverse factors, was noted in 51.6% (258/500) of patients. 36.8% (95/258) of patients with high risk for FN received primary prophylaxis with granulocyte colony-stimulating factors. \u0000Conclusion. The study showed a significant proportion of patients with a high risk of FN, and most of them do not receive primary prophylaxis of FN.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":"13 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138585266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutritional support in oncology: the place of parenteral nutrition (literature review)","authors":"I. Pasechnik, E. Skobelev, T. S. Boldyreva","doi":"10.26442/18151434.2023.3.202261","DOIUrl":"https://doi.org/10.26442/18151434.2023.3.202261","url":null,"abstract":"Currently nutritional support is considered as one of the most important components of the treatment of cancer patients. This is due to the positive effect of correction of nutritional status on the course of the underlying disease, the tolerability of antitumor treatment, rehabilitation measures and quality of life. The most important principle of nutritional support is its continuity at all stages of the patient's curation: polyclinic, inpatient, rehabilitation. The purpose of the review was to discuss nutritional support for cancer patients with an emphasis on parenteral nutrition. Out of more than 120 initially selected literature sources from various databases (Scopus, Web of science, RSCI, etc.), 55 sources were left for analysis mainly over the past 5 years, earlier publications were used while maintaining their informativeness for clinicians. The modern concept of parenteral nutrition implies the appointment of drugs “three in one”. Parenteral nutrition should include not only macronutrients, but also micronutrients: fat- and water-soluble vitamins, ω-3 fatty acids. It has been established that the development of infectious complications with nutritional support is not related to its type, but to the calorie intake. The issues of additional parenteral nutrition with inadequate enteral nutrition are examined. The clinician should personalize nutritional support taking into account the type of tumor process, its stage, the characteristics of the patient and the severity of eating disorders. During the treatment of patients with oncological diseases, it is necessary to assess the state of their nutritional status and, if necessary, carry out correction. The doctor is obliged to choose the optimal way to provide the patient with energy and plastic materials – oral supplemental nutrition, enteral nutrition, parenteral nutrition or a combination of them. Clinical practice shows that the rejection of parenteral nutrition is accompanied by a decrease in the quality of nutritional support. The choice of the type of nutritional support is based on the indications for its implementation, which are detailed in the clinical recommendations. Strict adherence to the algorithm of correction of nutritional status depending on the stage of cancer, the patient's condition, the type of antitumor therapy will optimize the results of treatment and improve the quality of life.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":"7 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138584980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resolution of the advisory board on the topic: “The place of entrectinib in the treatment of adult patients with NTRK-fusion positive solid tumors”","authors":"V. Breder, L. G. Zhukova, L. V. Bolotina, I.A. Demidova, Y. A. Zhulikov, E. Lubennikova, D. Naskhletashvili, Sergey Orlov, R. V. Orlova, Ilya S. Romanov, Nikita A. Savelov, K. A. Sarantseva, A. Tyulyandina, M. Fedyanin","doi":"10.26442/18151434.2023.3.202441","DOIUrl":"https://doi.org/10.26442/18151434.2023.3.202441","url":null,"abstract":"NTRK-fusion positive tumors are a rare finding, but targeted therapy demonstrates persistent and sustained systemic and intracranial responses to entrectinib. This resolution proposes algorithms for diagnosing NTRK translocations in various solid tumors and discuses clinical data on the efficacy and safety of entrectinib.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138982421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}